Memantine in the Treatment of Alzheimer’s Disease

• Hebert LE , ScherrPA, BieniasJL et al.: Alzheimer’s disease in the US population. Arch. Neurol.60(8), 1119–1122(2003).
   PubMed Web of Science ®Google Scholar
• Cummings JL , ColeG: Alzheimer disease.JAMA87(18), 2335–2338(2002).
   Google Scholar
• Butler SM , AshfordJW, SnowdonDA: Age, education, and changes in the Mini-Mental State Exam scores of older women: findings from the Nun Study.J. Am. Geriatr. Soc.44(6), 675–681(1996).
   PubMed Web of Science ®Google Scholar
• Riley KP , SnowdonDA, MarkesberyWR: Alzheimer‘s neurofibrillatory pathology and the spectrum of cognitive function: findings from the Nun Study.Ann. Neurol.51(5), 567–577(2002).
   PubMed Web of Science ®Google Scholar
• Greenamyre JT , MaragosWF, AlbinRL, PenneyJB, YoungAB: Glutamate transmission and toxicity in Alzheimer’s disease.Prog. Neuropsychopharmacol. Biol. Psychiatry12(4), 421–430(1988).
   PubMed Web of Science ®Google Scholar
• Rothman SM , ThurstonJH, HauhartRE: Delayed neurotoxicity of excitatory amino acids in vitro.Neuroscience22(2), 471–480(1987).
   PubMed Web of Science ®Google Scholar
• Scorziello A , MeucciO, FlorioT et al.: β25–35 Alters calcium homeostasis and induces neurotoxicity in cerebellar granule cells. J. Neurochem.66(5), 1995–2003(1996).
   PubMed Web of Science ®Google Scholar
• Mattson MP , ChengB, DavisD, BryantK, LieberburgI, RydelRE: β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity.J. Neurosci.12(2), 376–389(1992).
   PubMed Web of Science ®Google Scholar
• Velliquette RA , O‘ConnorT, VassarR: Energy inhibition elevates β-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer‘s disease pathogenesis.J. Neurosci.25(47), 10874–10883(2005).
   PubMed Web of Science ®Google Scholar
• Sindou P , LesortM, CouratierP, YardinC, EsclaireF, HugonJ: Glutamate increases tau phosphorylation in primary neuronal cultures from fetal rat cerebral cortex.Brain Res.646(1), 124–128(1994).
   PubMed Web of Science ®Google Scholar
• Couratier P , LesortM, SindouP, EsclaireF, YardinC, HugonJ: Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity.Mol. Chem. Neuropathol.27(3), 259–273(1996).
   PubMedGoogle Scholar
• Procter A : Abnormalities in non-cholinergic neurotransmitter systems in Alzheimer‘s disease. In:Dementia, 2nd Edition. O‘Brien J, Ames D, Burns A (Eds), Edward Arnold, London, UK 433–442(2000).
   Google Scholar
• Lipton SA : Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond.Nat. Rev. Drug Discov.5(2), 160–170(2006).
   PubMed Web of Science ®Google Scholar
• Cummings JL : Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.Am. J. Geriatr. Psychiatry11(2), 131–145(2003).
   PubMed Web of Science ®Google Scholar
• Schneider LS , TariotPN: Cognitive enhancers and treatments for Alzheimer‘s disease. In:Psychiatry, 2nd Edition. Tasman A, Kay J, Lieberman JA (Eds), John Wiley and Sons, London, UK, 2096–2108(2003).
   Google Scholar
• Cummings JL : Alzheimer‘s disease.N. Engl. J. Med.351(1), 56–67(2004).
   PubMed Web of Science ®Google Scholar
• Doody RS , StevensJC, BeckC et al.: Practice parameter: management of dementia (an evidence-based review). Neurology56(9), 1154–1166(2001).
   PubMed Web of Science ®Google Scholar
• Winblad B , JelicV: Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors.Alzheimer Dis. Assoc. Disord.18(Suppl. 1), S2–S8 (2004).
   PubMed Web of Science ®Google Scholar
• Tariot PN , FederoffHJ: Current treatment for Alzheimer disease and future prospects.Alzheimer Dis. Assoc. Disord.17(Suppl. 4), S105–S113 (2003).
   PubMed Web of Science ®Google Scholar
• Watkins PB , ZimmermanHJ, KnappMJ, GraconSI, LewisKW: Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease.JAMA271(13), 992–998(1994).
   PubMed Web of Science ®Google Scholar
• Gracon SI , KnappMJ, BerghoffWG et al.: Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis. Assoc. Disord.12(2), 93–101(1998).
   PubMed Web of Science ®Google Scholar
• Morris MC , EvansDA, BieniasJL, Tangney CC, Wilson RS: Vitamin E and cognitive decline in older persons. Arch. Neurol.59(7), 1125–1132(2002).
   PubMed Web of Science ®Google Scholar
• Englehart MJ , GeerlingsMI, RuitenbergA, van Swieten CJ, Hofman A, Witteman JCM: Dietary intake of antioxidants and risk of Alzheimer disease. JAMA287(24), 3223–3229(2002).
   PubMed Web of Science ®Google Scholar
• Sano M , ErnestoC, ThomasRG et al.: A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N. Engl. J. Med.336(17), 1216–1222(1997).
   PubMed Web of Science ®Google Scholar
• Lonn E , BoschJ, YusufS: Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.JAMA293(11), 1338–1347(2005).
   PubMed Web of Science ®Google Scholar
• Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med.142(1), 37–46(2005).
   PubMed Web of Science ®Google Scholar
• Schneider LS , DagermanK, InselPS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.Am. J. Geriatr. Psychiatry.14(3), 191–210(2006).
   PubMed Web of Science ®Google Scholar
• Wang PS , SchneeweissS, AvornJ et al.: Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N. Engl. J. Med.353(22), 2335–2341(2005).
   PubMed Web of Science ®Google Scholar
• Schenk D , BarbourR, DunnW et al.: Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature400(6740), 173–177(1999).
   PubMed Web of Science ®Google Scholar
• Games D , BardF, GrajedaH et al.: Prevention and reduction of AD-type pathology in PDAPP mice immunized with Aβ 1–42. Ann. N. Y. Acad. Sci.920, 274–284(2000).
   PubMed Web of Science ®Google Scholar
• Gilman S , KollerM, BlackRS et al.: Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology64(9), 1553–1562(2005).
   PubMed Web of Science ®Google Scholar
• Orgogozo JM , GilmanS, DartiguesJF et al.: Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology61(1), 46–54(2003).
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM , ScholtzovaH, MehtaPD, FrangioneB, WisniewskiT: Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer‘s disease-associated pathology in transgenic mice.Am. J. Pathol.159(2), 439–447(2001).
   PubMed Web of Science ®Google Scholar
• Bard F , CannonC, BarbourR et al.: Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med.6(8), 916–919(2000).
   PubMed Web of Science ®Google Scholar
• Vassar R : β-secretase (BACE) as a drug target for Alzheimer‘s disease.Adv. Drug. Deliv. Rev.54(12), 1589–1602(2002).
   PubMed Web of Science ®Google Scholar
• Tomita T , IwatsuboT: γ-secretase as a therapeutic target for treatment of Alzheimer‘s disease.Curr. Pharm. Des.12(6), 661–670(2006).
   PubMed Web of Science ®Google Scholar
• Eckert GP , WoodWG, MüllerWE: Statins: drugs for Alzheimer‘s disease?J. Neural. Transm.112(8), 1057–1071(2005).
   PubMed Web of Science ®Google Scholar
• Vekrellis K , YeZ, QiuWQ et al.: Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. J. Neurosci.20(5), 1657–1665(2000).
   PubMed Web of Science ®Google Scholar
• Behl C , MoosmannB: Oxidative nerve cell death in Alzheimer’s disease and stroke: antioxidants as neuroprotective compounds.Biol. Chem.383(3–4), 521–536(2002).
   PubMed Web of Science ®Google Scholar
• Stuchbury G , MunchG: Alzheimer‘s associated inflammation, potential targets and future therapies.J. Neural Transm.112(3), 429–453(2005).
   PubMed Web of Science ®Google Scholar
• Alvarez G , Munoz-MontanoJR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J: Regulation of tau phosphorylation and protection against β-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer’s disease. Bipolar Disord.4(3), 153–165(2002).
   PubMed Web of Science ®Google Scholar
• Tariot PN , LoyR, RyanJM, PorsteinssonA, IsmailS: Mood stabilizers in Alzheimer’s disease: symptomatic and neuroprotective rationales.Adv. Drug. Deliv. Rev.54(12), 1567–1577(2002).
   PubMed Web of Science ®Google Scholar
• Wenk GL , ParsonsCG, DanyszW: Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine.Behav. Pharmacol.17(5–6), 411–424(2006).
   PubMed Web of Science ®Google Scholar
• Winblad B , MöbiusHJ, StöfflerA: Glutamate receptors as a target for Alzheimer’s disease – are clinical results supporting the hope?J. Neural. Transm. Suppl.62, 217–225(2002).
   Google Scholar
• Parsons CG , DanyszW, QuackG: Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist – a review of preclinical data.Neuropharmacology38(6), 735–767(1999).
   PubMed Web of Science ®Google Scholar
• Disterhoft JF , WuWW, OhnoM: Biophysical alterations of hippocampal pyramidal neurons in learning, ageing and Alzheimer‘s disease.Ageing Res. Rev.3(4), 383–406(2004).
   PubMed Web of Science ®Google Scholar
• Danysz W , ParsonsCG, KornhuberJ, SchmidtWJ, QuackG: Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents – preclinical studies.Neurosci. Biobehav. Rev.21(4), 455–468(1997).
   PubMed Web of Science ®Google Scholar
• Danysz W , ParsonsCG, MöbiusHJ, Stöffler A, Quack G: Neuroprotective and symptomalogical action of memantine relevant for Alzheimer‘s disease – a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Res.2, 85–98(2000).
   PubMed Web of Science ®Google Scholar
• NAMENDATM, package insert. Forest Pharmaceuticals, Inc., MO, USA (2003).
   Google Scholar
• Winblad B , PoritisN: Memantine in severe dementia: results of the M-BEST Study (benefit and efficacy in severely demented patients during treatment with memantine).Int. J. Geriatr. Psychiatry.14(2), 135–146(1999).
   PubMed Web of Science ®Google Scholar
• Reisberg B , DoodyR, StöfflerA, SchmittF, FerrisS, MöbiusHJ: Memantine in moderate-to-severe Alzheimer’s disease.N. Engl. J. Med.348(14), 1333–1341(2003).
   PubMed Web of Science ®Google Scholar
• Reisberg B , DoodyR, StöfflerA, SchmittF, FerrisS, MöbiusHJ: A 24-week open-label extension study of memantine in moderate to sever Alzheimer disease.Arch. Neurol.63(1), 49–54(2006).
   PubMedGoogle Scholar
• Tariot PN , FarlowMR, GrossbergGT, GrahamSM, McDonaldS, GergelI: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil.JAMA291(3), 317–324(2004).
   PubMed Web of Science ®Google Scholar
• Cummings JL , SchneiderE, TariotPN, GrahamSM: Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.Neurology67(1), 57–63(2006).
   PubMed Web of Science ®Google Scholar
• Peskind ER , PotkinSG, PomaraN et al.: Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized controlled trial. Am. J. Geriatr. Psychiatry14(8), 704–715(2006).
   PubMed Web of Science ®Google Scholar
• McShane R , AreosaSA, MinakaranN: Memantine for dementia.Cochrane Database of Syst. Rev.CD003154(2), (2006).
   PubMed Web of Science ®Google Scholar
• Periclou AP , VenturaD, ShermanT, RaoN, AbramowitzWT: Lack of pharmacokinetic or pharmacodynamic interactions between memantine and donepezil.Ann. Pharmacother.38(9), 1389–1394(2004).
   PubMed Web of Science ®Google Scholar
• Wenk GL , QuackG, MoebiusHJ, Danysz W: No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci.66(12), 1079–1083(2000).
   PubMed Web of Science ®Google Scholar
• Hartmann S , MöbiusHJ: Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.Int. Clin. Psychopharmacol.18(2), 81–85(2003).
   PubMed Web of Science ®Google Scholar
• Periclou A , VenturaD, RaoN, Abramowitz W: Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin. Pharmacol. Ther.79(1), 134–143(2006).
   PubMed Web of Science ®Google Scholar
• Orgogozo JM , RigaudAS, StöfflerA, MöbiusHJ, ForetteF: Efficacy and safety of memantine in patients with mild to moderate vascular dementia.Stroke.33(7), 1834–1839(2002).
   PubMed Web of Science ®Google Scholar
• Wilcock G , MöbiusHJ, StöfflerA: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia.Int. Clin. Psychopharmacol.17(6), 297–305(2002).
   PubMed Web of Science ®Google Scholar

Websites

• Alzheimer‘s Association: Alzheimer‘s disease statistics – fact sheet www.alz.org
   Google Scholar
• Namenda tablets/oral solution product information www.fda.gov/medwatch/SAFETY/2006/ Apr_PIs/Namenda_PI.pdf
   Google Scholar
• EMEA Product Overview – Axura www.emea.europa.eu/humandocs/Humans/EPAR/axura/axura.htm
   Google Scholar
• Forest Laboratories Inc – Clinical Trial Registry, study MEM-MD-01 www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-01_final.pdf
   Google Scholar
• EMEA – Scientific discussion for procedure number EMEA/H/C/463/II/15 www.emea.eu.int/humandocs/PDFs/EPAR/ebixa/Ebixa-H-463-II-15-SD.pdf
   Google Scholar
• Alzheimer‘s Disease Education & Referral (ADEAR) Center: Alzheimer‘s Disease Medications Fact Sheet. NIH Publication No. 03–3431 www.nia.nih.gov/Alzheimers
   Google Scholar
• Merz – Press release: Alzheimer‘s substance memantine strengthens worldwide market position www.merz.com/press/press-releases/company/2005/08/10/01
   Google Scholar
• US FDA, Center for Drug Evaluation and Research – Index to Drug-Specific Information www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm
   Google Scholar
• European Medicines Agency – Human Medicines www.emea.eu.int/index/indexh1.htm
   Google Scholar
• Health Canada – Drugs and Health Products www.hc-sc.gc.ca/dhp-mps/index_e.html
   Google Scholar
• US FDA – News www.fda.gov/bbs/topics/NEWS/2006/NEW01491.html
   Google Scholar